Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Backed by the peer-reviewed clinical trials behind the active ingredients we prescribe: semaglutide and tirzepatide
)
Patients with genetic variations that enhance GLP-1 receptor signaling may feel full and nauseated more intensely at standard dosesa signal to start lower and titrate slowly rather than push toward higher doses
Patients should not confuse temporary dose-adjustment discomfort with treatment failure
Consider relaxing the target HbA1c level (see recommendations 1.5.7 and 1.5.8 and NICE's patient decision aid on type 2 diabetes: agreeing someone's blood glucose (HbA1c) target) on a case-by-case basis and in discussion with adults with type 2 diabetes, with particular consideration for people who are older or frailer, if: they are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy tight blood glucose control would put them at high risk if they developed hypoglycaemia, for example, if they are at risk of falling, they have impaired awareness of hypoglycaemia, or they drive or operate machinery as part of their job intensive management would not be appropriate, for example if they have significant comorbidities
You can find our current program prices, including physician-led care, nutrition therapy, and medication, under Programs and Prices
US$ 26.63
US$ 23.32
US$ 23.47
US$ 23.67
US$ 20.72
US$ 29.73
US$ 26.61
